These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24633761)

  • 1. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.
    Lenze EJ; Hershey T; Newcomer JW; Karp JF; Blumberger D; Anger J; Doré P; Dixon D
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):962-9. PubMed ID: 24633761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder.
    Lenze EJ; Dixon D; Mantella RC; Dore PM; Andreescu C; Reynolds CF; Newcomer JW; Butters MA
    Int J Geriatr Psychiatry; 2012 May; 27(5):454-62. PubMed ID: 21681817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.
    Young AH; Gallagher P; Watson S; Del-Estal D; Owen BM; Ferrier IN
    Neuropsychopharmacology; 2004 Aug; 29(8):1538-45. PubMed ID: 15127079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.
    Gallagher P; Watson S; Smith MS; Ferrier IN; Young AH
    Biol Psychiatry; 2005 Jan; 57(2):155-61. PubMed ID: 15652874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone.
    Belanoff JK; Jurik J; Schatzberg LD; DeBattista C; Schatzberg AF
    J Mol Neurosci; 2002; 19(1-2):201-6. PubMed ID: 12212781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis.
    Lombardo G; Enache D; Gianotti L; Schatzberg AF; Young AH; Pariante CM; Mondelli V
    Psychoneuroendocrinology; 2019 Dec; 110():104420. PubMed ID: 31499391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders.
    Roat-Shumway S; Wroolie TE; Watson K; Schatzberg AF; Rasgon NL
    J Affect Disord; 2018 Oct; 239():242-246. PubMed ID: 30025313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
    J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease.
    Pomara N; Hernando RT; de la Pena CB; Sidtis JJ; Cooper TB; Ferris S
    Neurochem Res; 2006 May; 31(5):585-8. PubMed ID: 16770728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
    Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
    J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder.
    Rosnick CB; Rawson KS; Butters MA; Lenze EJ
    Aging Ment Health; 2013; 17(4):432-40. PubMed ID: 23336532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid Receptor (GR) antagonism as disease-modifying treatment for MDD with childhood trauma: protocol of the RESET-medication randomized controlled trial.
    Linsen F; Broeder C; Sep MSC; Verhoeven JE; Bet PM; Penninx BWJH; Meijer OC; Vinkers CH
    BMC Psychiatry; 2023 May; 23(1):331. PubMed ID: 37170109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
    Mackin P; Gallagher P; Watson S; Young AH; Ferrier IN
    Aust N Z J Psychiatry; 2007 Apr; 41(4):321-6. PubMed ID: 17464718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.
    Fein HG; Vaughan TB; Kushner H; Cram D; Nguyen D
    BMC Endocr Disord; 2015 Oct; 15():63. PubMed ID: 26507877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.
    Mattsson C; Reynolds RM; Simonyte K; Olsson T; Walker BR
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1347-52. PubMed ID: 19141586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biological effects of mifepristone treatment for psychotic depression.
    Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF
    Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the glucocorticoid antagonist, mifepristone, on the consequences of withdrawal from long term alcohol consumption.
    Jacquot C; Croft AP; Prendergast MA; Mulholland P; Shaw SG; Little HJ
    Alcohol Clin Exp Res; 2008 Dec; 32(12):2107-16. PubMed ID: 18828802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
    Fleseriu M; Molitch ME; Gross C; Schteingart DE; Vaughan TB; Biller BM
    Endocr Pract; 2013; 19(2):313-26. PubMed ID: 23337135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness.
    Golier JA; Caramanica K; Michaelides AC; Makotkine I; Schmeidler J; Harvey PD; Yehuda R
    Psychoneuroendocrinology; 2016 Feb; 64():22-30. PubMed ID: 26600007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression.
    Watson S; Gallagher P; Porter RJ; Smith MS; Herron LJ; Bulmer S; ; Young AH; Ferrier IN
    Biol Psychiatry; 2012 Dec; 72(11):943-9. PubMed ID: 22770649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.